Mark Karbarz

Mark Karbarz has a diverse work experience spanning several companies and roles. Mark is currently serving as the Executive Director of Biologics Development and Head of CMC at Tallac Therapeutics since January 2021. Prior to that, they worked at Alexion Pharmaceuticals, Inc. as the Director of Global Product Development from July 2020 to the present.

From 2010 to 2020, Mark held various positions at Portola Pharmaceuticals, including Senior Director of Protein Biochemistry, Biologic DS Manufacturing, and CMC Strategy Lead. Mark also served as the Director of Biology and Protein Biochemistry and held roles as a Senior Scientist.

Before joining Portola Pharmaceuticals, Mark worked as a Scientist at Arete Therapeutics and Johnson and Johnson Pharmaceuticals. Mark also gained teaching experience as an Adjunct Faculty at Miramar College, where they primarily taught natural science classes.

Mark's professional journey started as a Scientist at Neurocrine Biosciences after completing their Postdoctoral Fellowship in Protein Biochemistry at the University of California-San Diego. Mark also pursued a graduate degree at Duke University, where they conducted research on membrane lipids in Escherichia coli and Rhizobium leguminosarum.

Additionally, Mark worked as a Contract Writer at Washington Info Source in 1999. Overall, they have accumulated extensive experience in biologics development, protein biochemistry, and pharmaceutical research throughout their career.

Mark Karbarz obtained a Bachelor of Science (BS) degree in Biochemistry from the University of Illinois Urbana-Champaign, where they studied from 1994 to 1998. Mark continued their education at Duke University from 1998 to 2004, completing a doctoral program and earning a PhD in Biochemistry and Biological Chemistry. Prior to their university studies, Mark attended Downers Grove South High School, but no specific start or end dates are provided for this period.